Measuring Health-Related Quality of Life in Patients Treated for Substance Dependence: Differences Among Instruments and Methods of Eliciting Preferences

Bibliographic citation

Eva Rodríguez-Míguez, Bruno Casal & Berta Rivera (2021) Measuring health-related quality of life in patients treated for substance dependence: differences among instruments and methods of eliciting preferences, Expert Review of Pharmacoeconomics & Outcomes Research, 21:4, 683-690, DOI: 10.1080/14737167.2020.1804872

Type of academic work

Academic degree

Abstract

[Abstract] Background: Measuring the health-related quality of life is an essential estimation in cost–utility studies. In this research, we provide new evidence about comparing utility scores – in the field of substance dependence. Although the main objective is to compare the EQ-5D-5L and SF-6D with paired gamble, evidence about the SF-6D with standard gamble is also provided. Methods: Ninety-four patients with substance dependence were recruited; the SF-6D and the EQ-5D-5L were administered at the beginning of treatment and 6 months thereafter. Differences in treatment effect were estimated by comparing utility gains. All analyses were reproduced for two subgroups of severity. Results: Both the baseline scores and the treatment effect are sensitive to the instrument used. For severe states, the SF-6D with paired gamble (SF-6D with standard gamble) estimates the lowest (highest) utility. With regard to the impact of treatment, the EQ-5D-5L and SF-6D with paired gamble estimate strongly similar effects for severe states (and both estimate greater effects than does the SF-6D with standard gamble). Conclusions: These findings have implications for cost–utility analyses. The incremental cost-utility ratio of treatments intended for severe states is barely sensitive to the choice of EQ-5D-5L or SF-6D with paired gamble.

Description

Rights

© 2020 Informa UK Limited, trading as Taylor & Francis Group